OBJECTIVE： To observe the efficacy and safety of tripterygium glycosides combined with mizolastine in the treatment of dermatitis and eczema. METHODS： 138 patients with dermatitis and eczema were randomly divided into control group （69 cases） and observation group （69 cases）. Control group received Mizolastine sustained release tablet 10 mg， orally， once a day. Observation group additionally received Tripterygium glycosides tablet 20-30 mg， orally taking after a meal， 3 times a day. All patients treated for 3 weeks， patients’ life way remained unchanged during treatment. Clinical efficacy， total score of symptoms， IL-2， IL-6， CRP levels and the incidence of adverse reactions in 2 groups were observed. RESULTS： The total effective rate in observation group was significantly higher than control group， with significant difference （P＜0.01）. After treatment， the total score of symptoms， IL-2， IL-6， CRP levels in 2 groups were significantly lower than before， and observation group was lower than control group， with significant differences （P＜0.05 or P＜0.01）. The incidence of adverse reactions in observation group was significantly lower than control group， with significant difference （P＜0.05）. CONCLUSIONS： Tripterygium glycosides combined with mizolastine shows better efficacy than mizolastine alone in the treatment of dermatitis and eczema， with better safety.